JPRN-jRCT2080222988已完成2 期
An Open-Label, Multicenter Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer who failed gemcitabine-based combination chemotherapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
In patients with unresectable BTC who had failed gemcitabine-based combination chemotherapy, lenvatinib 24 mg/day demonstrated antitumor activity. The oral administration of lenvatinib at a dose of 24 mg QD had an acceptable and manageable safety profile by following prespecified dose reduction or interruption instructions. The safety profile of lenvatinib monotherapy in this indication is generally consistent with the safety profile of lenvatinib monotherapy in other settings.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Pathologically or cytologically confirmed adenocarcinoma of biliary tract cancer (BTC; intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer and ampulla of Vater cancer)
- •2.Unresectable (e.g. locally advanced or metastatic) BTC
- •3.One prior gemcitabine-based doublet chemotherapy (e.g. gemcitabine and cisplatin) to unresectable BTC and not treated by any other chemotherapy to BTC
- •4.ECOG Performance Status of 0-1.
- •5.Survival expectation of 3 months or longer after beginning of study treatment
- •6.Males or females age >=20 years at the time of informed consent
- •7.All chemotherapy- or radiation-related toxicities must have resolved to Grade 0-1 per Common Terminology Criteria for Adverse Events (CTCAE v 4.03), except alopecia, infertility and the adverse events listed in inclusion criteria.
- •8.Adequately controlled blood pressure (BP) with or without antihypertensive medications
- •(defined as BP <=150/90 mm Hg at Screening and no change in antihypertensive medications within 1 week prior to the first dose of study drug)
- •9.Subjects with adequate function of major organs and blood coagulation:
- •10.Subjects must voluntarily agree to provide written informed consent
- •11.Subjects must be willing and able to comply with all aspects of the protocol
排除标准
- •1.Any anti-cancer treatment (except BSC) within 21 days prior to the first dose of study drug
- •2.Major surgery (any surgical procedure that involves anesthesia or respiratory assistance) within 21 days prior to the first dose of study drug or scheduled surgery during the study (except for bile duct drainage)
- •3.Ascites of moderate, severe or requiring drainage
- •4.Proteinuria of >=2+ on dipstick testing (Grade <= confirmed by quantitative assessment is eligible)
- •5.Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug
- •6.New York Heart Association congestive heart failure of class II or above, unstable angina, myocardial infarction or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months from the first dose of study drug.
- •7.A prolonged QT/QTc interval (QTcF>480 ms)
- •8.Known to be human immunodeficiency virus (HIV) positive
- •9.Active infection requiring systemic treatment
- •10.Bleeding or thrombotic disorders or chronic systemic use of anticoagulants requiring therapeutic INR monitoring, eg, warfarin or similar agents. (Treatment with low molecular weight heparin is permitted.)
- •11.Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 21 days prior to the first dose of study drug
- •12.Active malignancy (except for BTC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the cervix, or early stage gastric/colorectal cancer) within the past 24 months prior to the first dose of study drug
- •13.Diagnosed with meningeal carcinomatosis
- •14.Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 28 days prior to the first dose of study drug. Any signs (eg, radiologic) or symptoms of brain metastases must be stable for at least 28 days prior to the first dose of study drug.
- •15.Known intolerance to the study drug or any of the excipients
- •16.History of drug or alcohol dependency or abuse within the last 24 months prior to the first dose of study drug
- •17.Any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study
- •18.Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive human chorionic gonadotropin [hCG or beta-hCG]. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 3 days before the first dose of study drug.
- •19. For either males unless undergoing a successful vasectomy (confirmed azoospermia) or females of childbearing potential, the participant and his/her partner do not agree to use a medically appropriate method of contraception throughout the entire study period the use of condom, contraceptive sponge, contraceptive foam, contraceptive jelly, diaphragm, or intrauterine device, otherwise using oral contraceptive (percutaneous or transvaginal also allowed) for at least 28 days before the first dose of study drug
研究者
相似试验
进行中（未招募）
2 期
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerAdvanced Biliary Tract CancerNCT04727996Seoul National University Hospital43
招募中
2 期
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaAcute Leukemia of Ambiguous LineageB Acute Lymphoblastic LeukemiaNCT06317662National Cancer Institute (NCI)153
已完成
2 期
Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II StudyTime to ProgressionNCT00747097Cliniques universitaires Saint-Luc- Université Catholique de Louvain43
已完成
2 期
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)Advanced Solid TumorsTriple Negative Breast CancerBiliary Tract CancersColorectal CancerOvarian CancerPancreatic CancerGastric CancerGlioblastomaNCT03797326Merck Sharp & Dohme LLC611
尚未招募
2 期
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT06129955Sun Yat-sen University47